<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Torres, Vincente E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">REPRISE 3b Study in Enrollment Phase</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease in adults and is the fourth-leading cause of end-stage renal disease. The Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease [REPRISE 3b; NCT02160145] study's objective is to compare the efficacy of tolvaptan, a selective arginine vasopressin V2 receptor antagonist, with placebo in adults with ADPKD. Results are discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">49</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>